logo-loader
viewNetscientific PLC

Shares in NetScientific up strongly after portfolio company's drug is given Merck boost

NetScientific invested £1.76mln for a 14.85% shareholding in PDS Biotechnology

Netscientific PLC -

Shares in NetScientific PLC (LON: NSCI) doubled in value after it emerged that a drug developed by one of its portfolio companies will take a key role in a phase II clinical study planned by industry giant Merck.

PDS Biotechnology’s PDS0101 will be trialled in harness with Merck’s top-selling immunotherapy, KEYTRUDA, as a front-line treatment for recurrent or metastatic head and neck cancer and the high-risk human papillomavirus-16 infection. The move essentially fast-tracks PDS0101.

"This collaboration advancing PDS0101 into phase II studies clearly demonstrates the strength of the results from PDS's initial Phase I studies for PDS0101,” said Ian Postlethwaite, chief executive of NetScientific, which invested £1.76mln for a 14.85% shareholding in PDS.

"Merck is renowned in the field of immuno-oncology, and PDS0101 when working in combination with their leading treatment for cancer, KEYTRUDA®, has the potential to offer a new and exciting therapy for patients suffering from these devastating diseases."

In mid-afternoon trade the shares, which were ahead 100% at one point, were changing hands for 11.26p, up 80%.

Quick facts: Netscientific PLC

Price: 5.5 GBX

AIM:NSCI
Market: AIM
Market Cap: £4.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19

2 min read